Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 24, 2026 06:00 ET | Source: Yatiri Bio

Yatiri Bio Enters Exclusive Option to In-License Agreement with Oscotec for Denfivontinib in AML

Yatiri Bio is a precision medicine company focused on identifying and validating biomarkers that predict therapeutic response in oncology.
February 10, 2026 06:00 ET | Source: Yatiri Bio

Yatiri Bio Accurately Predicts AML Drug Response in Blinded Study Using Foghorn’s FHD-286

100% concordance between biomarker predictions and clinical outcomes raises the bar for patient stratification and precision medicine